Browse studies

Find your next paid study

53 recruiting studies matching your filters

(TESSERACT): Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation (TBI)

This phase I/II trial studies the side effects, safety, and effectiveness of low dose radiation to the entire body (total body irradiation \[TBI\]) and higher …

Extensive Stage Lung Small Cell CarcinomaStage IV Lung Cancer

Estimated

~$10 – $6,250

Vanderbilt-Ingram Cancer CenterNCT06110572

Phase 1

A Phase I Study of Osimertinib, Cetuximab, and Tucatinib in Advanced EGFR-Mutant NSCLC With Acquired Resistance to Osimertinib

This phase I trial tests the safety, side effects, and best dose of osimertinib, cetuximab, and tucatinib in treating patients with EFGR-mutant non-small cell …

Metastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

Estimated

~$10 – $7,500

Jonathan RiessNCT06067776

Phase 1

A Phase I/II Study Evaluating the Safety and Pharmacokinetics of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Lung Cancer During Surgical Procedures

This phase I/II trial studies the best dose and timing of panitumumab-IRDye800 in detecting cancer in participants with lung cancer during the surgery. Panitum…

Lung CarcinomaMetastatic Malignant Neoplasm in the LungStage IV Lung Cancer AJCC v8+2 more

Estimated

~$10 – $6,250

Stanford UniversityNCT03582124

Insomnia in Patients With Metastatic Non Small Cell Lung Cancer

This study evaluates how common insomnia (difficulties with sleep) is in patients with lung cancer that has spread from where it first started (primary site) t…

Metastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

Estimated

~$10 – $750

Mayo ClinicNCT06472804

Phase 2

A Randomized Phase II/III Study of Docetaxel and Ramucirumab With or Without Cemiplimab for Participants Previously Treated With Platinum-Based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alon…

Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

Estimated

~$10 – $7,500

SWOG Cancer Research NetworkNCT06616584